Engene Holdings Common Etf Profile
| ENGN Etf | USD 7.01 1.46 17.24% |
Performance3 of 100
| Odds Of DistressLess than 24
|
EnGene Holdings is selling at 7.01 as of the 11th of December 2024; that is 17.24 percent decrease since the beginning of the trading day. The etf's open price was 8.47. EnGene Holdings has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 11th of November 2024 and ending today, the 11th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of November 2023 | Category Healthcare | Classification Health Care |
EnGene Holdings is entity of United States. It is traded as Etf on NASDAQ exchange. The company has 50.98 M outstanding shares of which 769.44 K shares are currently shorted by private and institutional investors with about 5.74 trading days to cover. More on enGene Holdings Common
Moving against EnGene Etf
EnGene Etf Highlights
| CEO Director | JD Esq |
| Thematic Idea | Pharmaceutical Products (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation Analysts covering EnGene Holdings report their recommendations after researching EnGene Holdings' financial statements, talking to executives and customers, or listening in on EnGene Holdings' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering enGene Holdings Common. The EnGene consensus assessment is calculated by taking the average forecast from all of the analysts covering EnGene Holdings. | |
| Tax Provision | 17,000 |
| Logo U R L | imglogosUSENGN.png |
| Total Current Liabilities | 5.26 Million |
| Total Stockholder Equity | 72.49 Million |
| Currency Code | USD |
| Fiscal Year End | October |
| Stock Based Compensation | 3.45 Million |
| Property Plant And Equipment Net | 589,000 |
| Begin Period Cash Flow | 20.43 Million |
| Net Debt | (71.74 Million) |
| Accounts Payable | 1.16 Million |
| Cash | 81.52 Million |
| Other Operating Expenses | 26.06 Million |
| Non Current Assets Total | 1.52 Million |
| Non Currrent Assets Other | 860,000 |
| Long Term Debt | 9.22 Million |
| Cash And Short Term Investments | 81.52 Million |
| 50 Day M A | 8.0988 |
| Code | ENGN |
| Common Stock Shares Outstanding | 23.2 Million |
enGene Holdings Common [ENGN] is traded in USA and was established February 14, 2012. EnGene Holdings is listed under Biotechnology category by Fama And French industry classification. The fund is listed under Health Care category and is part of Biotechnology family. The entity is thematically classified as Pharmaceutical Products. This fund currently have 86.96 M in assets under management (AUM). enGene Holdings Common is currently generating year-to-date return of -0.98%, while the total return for the last 3 years was 3.14%.
EnGene Holdings generates negative cash flow from operations
Check EnGene Holdings Probability Of Bankruptcy
enGene Holdings Common Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in EnGene Holdings. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | 0.0434 | |||
| Jensen Alpha | 0.0405 | |||
| Total Risk Alpha | (0.58) | |||
| Sortino Ratio | 0.022 |
EnGene Holdings Against Markets
Other Information on Investing in EnGene Etf
EnGene Holdings financial ratios help investors to determine whether EnGene Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EnGene with respect to the benefits of owning EnGene Holdings security.